NeuBase Therapeutics Added to Russell 3000® and Russell Microcap® Indexes
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced its inclusion in the Russell 3000® and Russell Microcap® Indexes effective after the market opens on June 29, 2020. This membership reflects NeuBase's market capitalization and will enhance its visibility in the investment community. Membership in the Russell 3000® provides opportunities for automatic inclusion in the Russell 1000® or 2000® Indexes. The Russell indexes are benchmarks for $9 trillion in assets, widely used by institutional investors.
- Included in the Russell 3000® Index enhances visibility and exposure.
- Membership opens opportunities for automatic inclusion in Russell 1000® or 2000® Indexes.
- None.
PITTSBURGH, June 29, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that it has been added to the Russell 3000® and Russell Microcap® Indexes at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens today.
Membership in the all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8th, ranking them by total market capitalization.
“We are pleased to be included in the Russell Indexes. This milestone represents an opportunity to further increase our visibility and exposure within the broad investment community,” said Dietrich A. Stephan, Ph.D., chief executive officer of NeuBase.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
For more information on the Russell 3000® and Russell Microcap® Indexes, and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic diseases.
About FTSE Russell:
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
Use of Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
| NeuBase Investor Contact: | NeuBase Media Contact: | |
| Dan Ferry | Cait Williamson, Ph.D. | |
| Managing Director | LifeSci Communications | |
| LifeSci Advisors, LLC | cait@lifescicomms.com | |
| daniel@lifesciadvisors.com | OP: (646) 751-4366 | |
| OP: (617) 535-7746 |
FAQ
What does it mean for NBSE to be included in the Russell 3000® Index?
When did NeuBase get added to the Russell Microcap® Index?
How much in assets are benchmarked against Russell's indexes?
What is the significance of the Russell 3000® Index membership for NeuBase?
